1.69
8.40%
-0.155
Handel nachbörslich:
1.77
0.08
+4.73%
Schlusskurs vom Vortag:
$1.845
Offen:
$1.87
24-Stunden-Volumen:
407.47K
Relative Volume:
1.04
Marktkapitalisierung:
$43.92M
Einnahmen:
$210.70K
Nettoeinkommen (Verlust:
$-22.22M
KGV:
-0.9286
EPS:
-1.82
Netto-Cashflow:
$-17.13M
1W Leistung:
-22.12%
1M Leistung:
-37.41%
6M Leistung:
-35.74%
1J Leistung:
-37.41%
Gain Therapeutics Inc Stock (GANX) Company Profile
Firmenname
Gain Therapeutics Inc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie GANX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
GANX | 1.69 | 43.92M | 210.70K | -22.22M | -17.13M | -1.82 |
VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2021-04-12 | Eingeleitet | BTIG Research | Buy |
2021-04-12 | Eingeleitet | Oppenheimer | Outperform |
Gain Therapeutics Inc Aktie (GANX) Neueste Nachrichten
Stock market today: Fate Therapeutics gains 70.79% whereas SiNtx Technologies rose by 38.73% in early trading - Business Upturn
Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Up 15.1% in October - Defense World
PDS Biotechnology’s (PDSB) Buy Rating Reiterated at HC Wainwright - Defense World
Tapestry (NYSE:TPR) Price Target Raised to $66.00 - Defense World
Protara Therapeutics, Inc. (NASDAQ:TARA) Sees Large Increase in Short Interest - MarketBeat
Gain Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Pre-market Movers: GANX, TFFP, AKYA, CLDI... - RTTNews
Gain Therapeutics Inc (GANX) Quarterly 10-Q Report - Quartzy
Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update - The Manila Times
Gain Therapeutics' Parkinson's Drug Shows 53% Activity Boost in Phase 1 Trial | GANX Stock News - StockTitan
The Future Of Inflammation: The Inflammasome And Beyond - Citeline
Insiders of Tectonic Therapeutic, Inc. (NASDAQ:TECX) were rewarded after last week’s 10% gain - Simply Wall St
Endeavour Silver Corp (EXK) Forecast: Revisiting The Past To Gain Insights For The Future - Stocks Register
Individual investors who hold 54% of Galectin Therapeutics Inc. (NASDAQ:GALT) gained 12%, insiders profited as well - Simply Wall St
2024's 10 Best-Performing Stocks | Investing - U.S News & World Report Money
CAMP4 Analyst Highlights Rare Disease Platform Potential - Benzinga
U.S. Stock market: Zoomcar Holdings (+192.21%), Avalon GloboCare (+56.73%), and Vimeo (+40.85%) experience significant gains during mid day trading - Business Upturn
Canada Market top gains:Q2 Metals Corp rises 17.00% while Valeura Energy climbs 15.55% at midday - Business Upturn
Hoping for a weight-loss pill? It could get closer to reality next week. - MarketWatch
individual investors who own 55% along with institutions invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) saw increase in their holdings value last week - Yahoo Finance
Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Shares Bounce 27% But Its Business Still Trails The Industry - Simply Wall St
Amneal Pharmaceuticals (NASDAQ:AMRX) grows 3.0% this week, taking five-year gains to 211% - Yahoo Finance
Tarsus Pharmaceuticals (TARS) Surges 10.6%: Is This an Indication of Further Gains? - Yahoo Finance
Short Interest in Gain Therapeutics, Inc. (NASDAQ:GANX) Decreases By 12.6% - MarketBeat
Vertex Pharmaceuticals (VRTX) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
Nuclear stocks gain on AI optimism: Oklo, NuScale, Centrus - Yahoo Finance
Investing in Arcturus Therapeutics Holdings (NASDAQ:ARCT) five years ago would have delivered you a 76% gain - Yahoo Finance
Gain Therapeutics Presents Data at 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2 - The Manila Times
What Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 26% Share Price Gain Is Not Telling You - Simply Wall St
Gain Therapeutics Regains Nasdaq Compliance - Investing.com
Gain Therapeutics Regains Nasdaq Compliance By Investing.com - Investing.com UK
The Manufacturers Life Insurance Company Acquires 6,328 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider - MSN
32 NMEs gain US FDA clearance through Q3, approvals up over 2023 - BioWorld Online
Viking Therapeutics, Inc. (VKTX) Outpaces Stock Market Gains: What You Should Know - MSN
How should investors view Janux Therapeutics Inc (JANX)? - US Post News
What was Gain Therapeutics Inc (GANX)’s performance in the last session? - US Post News
Gain Therapeutics Inc [GANX] Investment Guide: What You Need to Know - Knox Daily
GANX Stock: A Voyage Through Gain Therapeutics Inc’s Finances - The InvestChronicle
Can you now get a good deal on Compass Therapeutics Inc’s shares? - US Post News
Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - The Manila Times
Renaissance Technologies LLC Boosts Holdings in Exagen Inc. (NASDAQ:XGN) - Defense World
Renaissance Technologies LLC Has $152,000 Stock Position in Gain Therapeutics, Inc. (NASDAQ:GANX) - Defense World
Investing in Voyager Therapeutics (NASDAQ:VYGR) three years ago would have delivered you a 58% gain - Yahoo Finance
Boeing, Nurix Therapeutics And 3 Stocks To Watch Heading Into Monday - Benzinga
Edgewise Therapeutics Inc (EWTX) Stock: Navigating Drops and Gains - The InvestChronicle
Seres Therapeutics gains amid takeover speculation - Seeking Alpha
GT-02287 may slow Parkinson’s progression, new early data suggest - Parkinson's News Today
Soleno Therapeutics Inc [SLNO] Revenue clocked in at $0.00 million, up 29.12% YTD: What’s Next? - The DBT News
PTC Therapeutics (PTCT) Surges 16.5%: Is This an Indication of Further Gains? - Yahoo
Gain Therapeutics to Present at Michael J. Fox Foundation's 16th Annual Parkinson's Disease Therapeutics Conference - The Manila Times
Finanzdaten der Gain Therapeutics Inc-Aktie (GANX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):